1. Current State of Equipoise: The New Era of Novel Oral Anticoagulants

2. Current State of Equipoise: The New Era of Novel Oral Anticoagulants

3. The New Era of Secondary Prevention After ACS

4. The New Era of Secondary Prevention After ACS

5. Prevention of Stent Thrombosis UA/Non-STEMI: Pharmacological Strategies

6. The New Era of Secondary Prevention After ACS

7. The Warfarin Paralysis in ACS

8. The Warfarin Paralysis in ACS

9. The Warfarin Paralysis in ACS

10. The Warfarin Paralysis in ACS

11. The Bleeding Conundrum in ACS

12. The Bleeding Conundrum in ACS

13. The New Era of Secondary Prevention after ACS

14. The Case for Not Switching: Stay on Xa Inhibition

15. The Case for Not Switching: Stay on Xa Inhibition

16. The Case For Not Switching: Stay on Xa Inhibition

17. The Case For Not Switching: Stay on Xa Inhibition

18. The Case for Switching: PCI with Bivalirudin

19. The New Era of Secondary Prevention After ACS

20. Combining Second-Generation ADP Antagonists With Second-Generation Oral Anticoagulants: A Fourth-Level Challenge

21. Combining Second-Generation ADP Antagonists With Second-Generation Oral Anticoagulants: A Fourth-Level Challenge

22. PLATO and ATLAS: The Philosopher Meets the Greek Titan

23. The New Era of Secondary Prevention After ACS

24. Challenges in Treating Contemporary ACS and the Need for Anticoagulation

25. Challenges in Treating Contemporary ACS and the Need for Anticoagulation

26. Challenges in Treating Contemporary ACS and the Need for Anticoagulation

27. Challenges in Treating Contemporary ACS and the Need for Anticoagulation

28. Efficacy and Safety With Warfarin Narrow Therapeutic Window

29. Consensus Statement for Selecting Warfarin vs ASA + Clopidogrel and DES vs BMS

30. The New Era of Secondary Prevention After ACS: Conclusion